Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) Protocol
Brief description of study
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EO-nonAD) participants,and (3) cognitively normal (CN) control participants. At this time the study is only enrolling participants with cognitive impairments.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's Disease,Mild Cognitive Impairment
-
Age: Between 40 Years - 64 Years
-
Gender: All
Updated on
22 Aug 2023.
Study ID: 829602